StageSeries A
Raised$53.5M
Founded2022
Employees22
LocationCambridge, MA
ValuationNot publicly available
About
We aim to improve the lives of millions of people living with obesity and related comorbidities by advancing a pipeline of best-in-class biologics. We combine cutting-edge protein engineering with deep mechanistic insight to address biological targets that have been validated but not yet fully exploited, ultimately changing the way metabolic disease is treated.
Product
- Value proposition
- A pipeline of best-in-class biologics targeting obesity and metabolic disease to improve body composition and metabolic health.
Founders
- Geoff MacKay — CEO
- Philip Kim — Co-founder and CTO
Categories
BiotechMetabolic DiseaseBiologicsProtein Engineering
Products
FBL-140 (ActR2A/B antagonist mAb)multifunctional conjugate pairing ActR2A/B antagonism with incretin mimetic
Key features
ActR2 pathway targetingantagonist monoclonal antibodymultifunctional conjugatespipeline approach for obesity and metabolic healthearly clinical entry anticipated 2027
Technologies
protein engineeringActR2 pathway modulationantibody therapeuticsbiologics pipeline development
Target conditions
Obesitymetabolic syndromecardiometabolic diseasesrelated comorbidities
Care settings
clinical developmentresearch & developmentclinic (through future products)
Traction metrics
lead program FBL-140 to begin clinic in early 2027pipeline focus on weight loss and metabolic remodeling
Competitors
other obesity/metabolic disease biotech companies targeting ActR2 pathwaybiologics developers in metabolic health
News
- Fable Therapeutics Appoints David J. Baker, PhD, as Chief Scientific Officer · 2025-06-09T12:00:00.000Z
- Fable Therapeutics Appoints Former AstraZeneca Executive David J. Baker as Chief Scientific Officer - MedPath Trial · 2025-06-09T17:04:03.000Z
- Fable Therapeutics Secures $53.5 Million in Funding to Revolutionize Drug Discovery with AI Integration | Signalbase · 2024-11-05T14:21:32.000Z
- Philip Kim · 2026-06-12T02:00:36.000Z
- Fable Therapeutics Secures $53.5 Million in Funding to Revolutionize Drug Discovery with AI Integration | Signalbase · 2024-11-05T14:21:32.000Z
- AI Drug Discovery Startups Reach Record Valuations | postmyblogs · 2025-11-25T07:12:00.000Z
Browse similar startups
Related startups
- FlowRx.ai — Needham, MA
- Genomes2People — Boston, MA
- Gordion Bioscience — Boston, MA
- Hampshire Dermatology and Skin Health Center — Northampton, MA
- Haver AI Inc. — Cambridge, MA
- HOLYOKE PEDIATRIC ASSOCIATES, LLP — Holyoke, MA
- FAMILY EYE CARE AND PEDIATRIC VISION CENTER, PLLC — Kingsport, TN
- FemHealth Insights — Cary, NC
- FemTech Collective — Oakland, CA
- FidaLab, LLC — Seattle, WA
- FillPoint Health — Dublin, OH
- finally skincare — Nashville, TN
Profile updated Jul 29, 2026. Sources: fabletherapeutics.com
